[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339205-105":59,"doc-detail-339205-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","activated-nad-biosynthesis-pathway-induces-olaparib-resistance-in-brca1-knockout-pancreatic-cancer-cells","Activated NAD+ biosynthesis pathway induces olaparib resistance in BRCA1 knockout pancreatic cancer cells","","PARP inhibitors act as anti-cancer agents through synthetic lethality in homologous recombination–deficient cells, but clinical resistance to drugs such as olaparib limits durable benefit. Mechanistic investigation used a BRCA1 knockout clone from MIA PaCa-2 (C1), followed by isolation of an olaparib-resistant C1/OLA derivative. RNA sequencing and pathway analysis identified activation of NAD+ metabolism signaling, with increased NAMPT and NMNAT2 expression, and higher intracellular NAD+ levels in C1/OLA cells. Nicotinamide-mediated NAD+ upregulation also induced resistance to olaparib and talazoparib in C1 cells.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/activated-nad-biosynthesis-pathway-induces-olaparib-resistance-in-brca1-knockout-pancreatic-cancer-cells/339205/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/activated-nad-biosynthesis-pathway-induces-olaparib-resistance-in-brca1-knockout-pancreatic-cancer-cells/339205.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address?","Question",{"text":112,"@type":113},"Resistance to PARP inhibitors such as olaparib remains a clinical problem, and the underlying mechanisms are not fully understood.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the resistant cells generated?",{"text":117,"@type":113},"A BRCA1 knockout clone derived from pancreatic cancer MIA PaCa-2 cells (C1) was established, and an olaparib-resistant variant (C1/OLA) was isolated.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism links NAD+ metabolism to PARP inhibitor resistance?",{"text":121,"@type":113},"Olaparib-resistant cells showed activation of NAD+ metabolism with increased expression of NAD+ biosynthetic enzymes NAMPT and NMNAT2, higher intracellular NAD+ levels, and nicotinamide-induced NAD+ upregulation that promoted resistance to olaparib and talazoparib.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339205,1790132399,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","PLOS ONE  \nOPEN ACCESS  \nCitation: Sasaki Y, Inouchi T, Nakatsuka R, Inoue A, Masutani M, Nozaki T (2024) Activated NAD+ biosynthesis pathway induces olaparib resistance in BRCA1 knockout pancreatic cancer cells. PLoSONE 19(4): e0302130 . [https://doi.org/10.1371/](https://doi.org/10.1371/)[ ](https://doi.org/10.1371/)[journal.pone.0302130](journal.pone.0302130)  \nEditor: Julie Decock, Qatar Biomedical Research Institute, QATAR  \nReceived: July 13, 2023  \nAccepted: March 28, 2024  \nPublished: April 16, 2024  \nCopyright: © 2024 Sasaki et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData Availability Statement: All relevant data are within the manuscript and its Supporting Information files.  \nFunding: This work was supported by JSPSKAKNEHI Grant Numbers JP20K16388 and JP22K10184 and The Uehara Memorial Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.  \nRESEARCH ARTICLE  \nActivated NAD+ biosynthesis pathway inducesolaparib resistance in BRCA1 knockout pancreatic cancer cells  \nYuka Sasaki1,2 *, Takuma Inouchi1, Ryusuke Nakatsuka1, Amane Inoue1, Mitsuko Masutani2, Tadashige Nozaki1  \n1 Department of Pharmacology, Faculty of Dentistry, Osaka Dental University, Hirakata, Osaka, Japan, 2 Department of Molecular and Genomic Biomedicine, Center for Bioinformatics and Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Sakamoto, Nagasaki, Japan  \n* [sasaki-y@cc.osaka-dent.ac.jp](sasaki-y@cc.osaka-dent.ac.jp)  \nAbstract  \nPARP inhibitors have been developed as anti-cancer agents based on synthetic lethality in homologous recombination deficient cancer cells. However, resistance to PARP inhibitors such as olaparib remains a problem in clinical use, and the mechanisms of resistance are not fully understood. To investigate mechanisms of PARP inhibitor resistance , we established a BRCA1 knockout clone derived from the pancreatic cancer MIA PaCa-2 cells, which we termed C1 cells, and subsequently isolated an olaparib-resistant C1/OLA cells. We then performed RNA-sequencing and pathway analysis on olaparib-treated C1 and C1/ OLA cells. Our results revealed activation of cell signaling pathway related to NAD+ metabolism in the olaparib-resistant C1/OLA cells, with increased expression of genes encoding the NAD+ biosynthetic enzymes NAMPT and NMNAT2 . Moreover, intracellular NAD+ levels were significantly higher in C1/OLA cells than in the non-olaparib-resistant C1 cells. Upregulation of intracellular NAD+ levels by the addition of nicotinamide also induced resistance toolaparib and talazoparib in C1 cells. Taken together, our findings suggest that upregulation of intracellular NAD+ is one of the factors underlying the acquisition of PARP inhibitor resistance.  \nIntroduction  \nPoly ADP-ribosylation (PARylation) is a post-translational modification that contributes to various biological functions, including DNA repair of single-strand breaks (SSBs) and doublestrand breaks (DSBs), transcriptional regulation, histone modification, and cell death [ 1–3] . This reaction is catalyzed by poly (ADP-ribose) polymerase (PARP) family proteins such as PARP1 and PARP2, which use β-nicotinamide adenine dinucleotide (NAD+) as a substrate to produce long ADP-ribose chains that are then added to target proteins [4, 5] . Degradation of poly (ADP-ribose) to ADP-ribose by the enzymes poly (ADP-ribose) glycohydrolase (PARG) and ADP-ribosyl hydrolase 3 regulates the various functions affected by PARylation [6–8] .  \nCompeting interests: The authors have declared that no competing interests exist.  \nPARP inhibitors that target PARP1/2, such as olaparib and talazoparib, have been approved as an","cbCaiv1eqizIOXqn","https://ap.wps.com/l/cbCaiv1eqizIOXqn","pdf",2351197,17,"English","# Abstract\n# Introduction\n## PARylation and PARP function\n## PARP inhibitors and clinical context\n## Resistance mechanisms","[{\"question\":\"What problem does the study address?\",\"answer\":\"Resistance to PARP inhibitors such as olaparib remains a clinical problem, and the underlying mechanisms are not fully understood.\"},{\"question\":\"How were the resistant cells generated?\",\"answer\":\"A BRCA1 knockout clone derived from pancreatic cancer MIA PaCa-2 cells (C1) was established, and an olaparib-resistant variant (C1/OLA) was isolated.\"},{\"question\":\"What mechanism links NAD+ metabolism to PARP inhibitor resistance?\",\"answer\":\"Olaparib-resistant cells showed activation of NAD+ metabolism with increased expression of NAD+ biosynthetic enzymes NAMPT and NMNAT2, higher intracellular NAD+ levels, and nicotinamide-induced NAD+ upregulation that promoted resistance to olaparib and talazoparib.\"}]","Activated NAD+ biosynthesis pathway induces olaparib resistance in BRCA1 knockout pancreatic cancer cells | PDF",1790028666,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/68db59059ce4b96612c08f08d09a47f2.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/052b8d0d092d8f07a1a2be1428c02788.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f59667500f356295de9a9a8271856100.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ab8bd34414c6ec838769bae89eec2176.webp",980,1268]